Onkologie. 2025:19(1):11-14 | DOI: 10.36290/xon.2025.002

Interstitial HDR brachytherapy of penile cancer

Denisa Pohanková, Igor Sirák, Miroslav Hodek, Petr Paluska, Jakub Grepl, Linda Kašaová, Martina Šůnová, Miroslava Čapková, Jiří Petera
Klinika onkologie a radioterapie, FN Hradec Králové

Interstitial high-dose rate brachytherapy (HDR BRT) is a promising treatment method for early-stage penile cancer, which in many cases serves as an alternative to primary surgical treatment. This technique allows for the preservation of the penis integrity in up to 80% of patients who would otherwise require radical surgery. As a result, patients experience not only a better quality of life but also significantly fewer post-treatment psychological issues. An important benefit is also the ability to maintain sexual function at a level comparable to that before the treatment.

Keywords: interstitial brachytherapy, early penile cancer, HDR brachytherapy.

Accepted: February 27, 2025; Published: March 10, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pohanková D, Sirák I, Hodek M, Paluska P, Grepl J, Kašaová L, et al.. Interstitial HDR brachytherapy of penile cancer. Onkologie. 2025;19(1):11-14. doi: 10.36290/xon.2025.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF

    References

    1. Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing World. Lancet Oncol. 2004; 5(4):240-247. Go to original source... Go to PubMed...
    2. Mosconi AM, Roila F, Gatta G, et al. Cancer of the penis. Crit Rev Oncol Hematol. 2005;53(2):165-177. Go to original source... Go to PubMed...
    3. Douglawi A, Masterson TA. Updates on the epidemiology and risk factors for penile cancer. Transl Androl Urol. 2017;6(5):785-790. Go to original source... Go to PubMed...
    4. Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, et al. Incidence trends in primary malignant penile cancer. Urol Oncol Semin Orig Investig. 2007;25(5):361-367. Go to original source... Go to PubMed...
    5. Büchler T. In: Speciální onkologie. Praha: Maxdorf, s r. o.; 2020.
    6. Maddineni SB, Lau MM, Sangar VK. Identifying the needs of penile cancer sufferers: A systematic review of the quality of life, psychosexual and psychosocial literature in penile cancer. BMC Urol. 2009;9(1):8. Go to original source... Go to PubMed...
    7. Korzeniowski MA, Crook JM. Contemporary role of radiotherapy in the management of penile cancer. Transl Androl Urol. 2017;6(5):855-867. Go to original source... Go to PubMed...
    8. Pohanková D, Sirák I, Vošmik M, et al. High-Dose-Rate Brachytherapy as an Organ-Sparing Treatment for Early Penile Cancer. Cancers. 2022;14(24):6248. Go to original source... Go to PubMed...
    9. Petera J, Sirák I, Kašaová L, et al. High-dose rate brachytherapy in the treatment of penile carcinoma--first experience. Brachytherapy. 2011;10(2):136-140. https://doi.org/10.1016/j.brachy.2010.05.007. Go to original source... Go to PubMed...
    10. Martz N, Bodokh Y, Gautier M, et al. High-dose rate brachytherapy in localized penile cancer: 5-Year clinical outcome analysis. Clin Transl Radiat Oncol. 2021;27:89-95. Go to original source... Go to PubMed...
    11. Marbán M, Crook J, Keyes M, et al. High-dose-rate brachytherapy for localized penile cancer: Evolution of a technique. Brachytherapy. 2020;19(2):201-209. Go to original source... Go to PubMed...
    12. Hasan S, Francis A, Hagenauer A, et al. The role of brachytherapy in organ preservation for penile cancer: A meta-analysis and review of the literature. Brachytherapy. 2015;14(4):517-524. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.